Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4

• Egile Nagusiak: Cécile Philippe (Egilea), Severin Mairinger (Egilea), Verena Pichler (Egilea), Johann Stanek (Egilea), Lukas Nics (Egilea), Markus Mitterhauser (Egilea), Marcus Hacker (Egilea), Thomas Wanek (Egilea), Oliver Langer (Egilea), Wolfgang Wadsak (Egilea)
• Formatua: Liburua
• Argitaratua: SpringerOpen, 2018-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background [11C]erlotinib has been proposed as a PET tracer to visualize the mutational status of the epidermal growth factor receptor (EGFR) in cancer patients. For clinical use, a stable, reproducible and high-yielding radiosynthesis method is a prerequisite. In this work, two production...